Efficient allocation of novel agents in multiple myeloma: a work in progress

about

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.

P2860

Q28547963-DD420D2B-8645-4EF3-B11C-BB511086C80B Q41042198-90889273-F77E-42B4-84B3-E47ABFD9FF95

P2860

Efficient allocation of novel agents in multiple myeloma: a work in progress

Item

http://www.wikidata.org/entity/Q36565638

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Efficient allocation of novel agents in multiple myeloma: a work in progress

@ast

Efficient allocation of novel agents in multiple myeloma: a work in progress

@en

type

Item

label

Efficient allocation of novel agents in multiple myeloma: a work in progress

@ast

Efficient allocation of novel agents in multiple myeloma: a work in progress

@en

prefLabel

Efficient allocation of novel agents in multiple myeloma: a work in progress

@ast

Efficient allocation of novel agents in multiple myeloma: a work in progress

@en

P1476

Efficient allocation of novel agents in multiple myeloma: a work in progress

@en

P2093

Carin A Uyl-de Groot

http://www.w3.org/2001/XMLSchema#string

Jennifer G Gaultney

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Improved survival in multiple myeloma and the impact of novel therapies.

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.

P304

5-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2012-0484

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234089415

http://www.w3.org/2001/XMLSchema#string

P698

23299778

http://www.w3.org/2001/XMLSchema#string

P932

3556256

http://www.w3.org/2001/XMLSchema#string

Efficient allocation of novel agents in multiple myeloma: a work in progress

about

P2860

P2860

Efficient allocation of novel agents in multiple myeloma: a work in progress

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932